BR112014011229A2 - composições e métodos para o tratamento de citomegalovírus - Google Patents

composições e métodos para o tratamento de citomegalovírus

Info

Publication number
BR112014011229A2
BR112014011229A2 BR112014011229A BR112014011229A BR112014011229A2 BR 112014011229 A2 BR112014011229 A2 BR 112014011229A2 BR 112014011229 A BR112014011229 A BR 112014011229A BR 112014011229 A BR112014011229 A BR 112014011229A BR 112014011229 A2 BR112014011229 A2 BR 112014011229A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treatment
hcmv
cytomegalovirus
Prior art date
Application number
BR112014011229A
Other languages
English (en)
Other versions
BR112014011229B1 (pt
Inventor
Fluckiger Anne-Catherine
E Anderson David
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Priority to BR122019027913-6A priority Critical patent/BR122019027913B1/pt
Publication of BR112014011229A2 publication Critical patent/BR112014011229A2/pt
Publication of BR112014011229B1 publication Critical patent/BR112014011229B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)

Abstract

resumo composições e métodos para o tratamento de citomegalovírus a presente revelação fornece composições e métodos úteis para o tratamento de infecção por hcmv. como aqui descrito, as composições e métodos se baseiam no desenvolvimento de composições imunogênicas que incluem partículas vírus-like (vlps) que compreendem uma ou mais proteínas centrais do vírus de leucemia murídea de moloney (mmlv) e incluem um ou mais epitopos do hcmv como, por exemplo, de glicoproteínas do envelope gb e/ou gh e/ou proteína do tegumento pp65 do hcmv. entre outras coisas, a presente invenção engloba o reconhecimento de que uma combinação de antígenos (por exemplo, glicoproteínas do envelope e proteínas estruturais) pode levar a respostas imunes benéficas, por exemplo, que incluem tanto uma resposta humoral (por exemplo, produção de anticorpos neutralizantes) quanto uma resposta celular (por exemplo, ativação de célula t).
BR112014011229-0A 2011-11-11 2012-11-09 Partículas vírus-like (vlp), composição farmacêutica compreendendo a referida partícula, método de produção e uso da mesma BR112014011229B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019027913-6A BR122019027913B1 (pt) 2011-11-11 2012-11-09 Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Publications (2)

Publication Number Publication Date
BR112014011229A2 true BR112014011229A2 (pt) 2017-05-09
BR112014011229B1 BR112014011229B1 (pt) 2021-10-13

Family

ID=48290708

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014011229-0A BR112014011229B1 (pt) 2011-11-11 2012-11-09 Partículas vírus-like (vlp), composição farmacêutica compreendendo a referida partícula, método de produção e uso da mesma
BR122019027913-6A BR122019027913B1 (pt) 2011-11-11 2012-11-09 Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019027913-6A BR122019027913B1 (pt) 2011-11-11 2012-11-09 Partícula vírus-like, composição farmacêutica compreendendo a referida partícula e método para produção da mesma

Country Status (14)

Country Link
US (3) US9777043B2 (pt)
EP (2) EP3854416A1 (pt)
JP (2) JP6232544B2 (pt)
KR (2) KR102301463B1 (pt)
CN (3) CN104271745A (pt)
AU (3) AU2012335277B2 (pt)
BR (2) BR112014011229B1 (pt)
CA (2) CA2889659C (pt)
DK (1) DK2776567T3 (pt)
ES (1) ES2874233T3 (pt)
MX (1) MX353189B (pt)
PT (1) PT2776567T (pt)
RU (2) RU2737530C1 (pt)
WO (1) WO2013068847A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936606A1 (en) 2009-06-18 2022-01-12 Kiyatec Inc. Bioreactor system
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2737530C1 (ru) * 2011-11-11 2020-12-03 Вэриэйшн Биотекнолоджиз, Инк. Композиции и способы для лечения цитомегаловируса
WO2013090648A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
JP6265344B2 (ja) 2012-03-27 2018-01-24 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 抗サイトメガロウイルス中和抗体の検出方法
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US8999380B2 (en) 2012-04-02 2015-04-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
ES2736500T3 (es) 2014-06-18 2020-01-02 Morphosys Ag Proteínas de fusión y usos de las mismas
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
US12060391B2 (en) 2015-03-16 2024-08-13 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2017068077A1 (en) 2015-10-20 2017-04-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
EP3364981A4 (en) * 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) * 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
JP6980780B2 (ja) 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
EP3784276A4 (en) * 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. SCALABLE CHROMATOGRAPHY METHOD FOR THE PURIFICATION OF HUMAN CYTOMEGALOVIRUS
CN112638411A (zh) * 2018-05-04 2021-04-09 斯拜生物技术有限公司 疫苗组合物
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3142110A1 (en) * 2019-05-31 2020-12-03 Variation Biotechnologies Inc. Immunotherapeutic compositions for treatment of glioblastoma multiforme
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
TW202413391A (zh) 2020-06-21 2024-04-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
WO1989007143A1 (en) * 1988-01-29 1989-08-10 Chiron Corporation Recombinant cmv neutralizing proteins
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
DE60031874D1 (de) * 1999-09-30 2006-12-28 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
WO2004058166A2 (en) 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
DE602004021260D1 (de) 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP2044224A4 (en) 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line
US20110250675A1 (en) 2008-03-26 2011-10-13 Life Technologies Corporaiton Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en) * 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
RU2737530C1 (ru) 2011-11-11 2020-12-03 Вэриэйшн Биотекнолоджиз, Инк. Композиции и способы для лечения цитомегаловируса
CA2931853C (en) * 2013-12-11 2023-10-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein b, protein complexes comprising trimeric gb and their use as vaccines

Also Published As

Publication number Publication date
CN107875382B (zh) 2024-03-08
MX353189B (es) 2018-01-05
CN107875382A (zh) 2018-04-06
RU2019139064A (ru) 2020-01-27
US20140308308A1 (en) 2014-10-16
US20170349634A1 (en) 2017-12-07
WO2013068847A3 (en) 2014-10-30
BR112014011229B1 (pt) 2021-10-13
KR102301463B1 (ko) 2021-09-14
AU2018203538A1 (en) 2018-06-07
JP6232544B2 (ja) 2017-11-22
KR20190104644A (ko) 2019-09-10
KR20140095556A (ko) 2014-08-01
JP6657150B2 (ja) 2020-03-04
EP2776567B1 (en) 2021-01-20
KR102340558B1 (ko) 2021-12-21
US9777043B2 (en) 2017-10-03
CA2889659A1 (en) 2013-05-16
RU2737530C1 (ru) 2020-12-03
CA2889659C (en) 2023-03-14
US11248026B2 (en) 2022-02-15
ES2874233T3 (es) 2021-11-04
AU2020264275A1 (en) 2020-11-26
CN104271745A (zh) 2015-01-07
EP3854416A1 (en) 2021-07-28
AU2020264275B2 (en) 2023-12-14
CN111995664A (zh) 2020-11-27
JP2015505299A (ja) 2015-02-19
BR122019027913B1 (pt) 2021-11-30
EP2776567A4 (en) 2015-12-30
US20230272013A1 (en) 2023-08-31
JP2018023374A (ja) 2018-02-15
PT2776567T (pt) 2021-05-25
CN111995664B (zh) 2024-08-02
EP2776567A2 (en) 2014-09-17
AU2012335277A1 (en) 2014-06-12
DK2776567T3 (da) 2021-04-26
CA3166278A1 (en) 2013-05-16
MX2014005653A (es) 2014-09-04
AU2012335277B2 (en) 2018-06-14
WO2013068847A2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BR112014011229A2 (pt) composições e métodos para o tratamento de citomegalovírus
AU2017297757A1 (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
JOP20200091A1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
TN2017000133A1 (en) Modified virus-like particles of cmv
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
MY173004A (en) Mycobacterial antigen vaccine
WO2013063366A3 (en) Methods for screening viral like particles and identifying neutralizing epitopes and related vaccines, constructs, and libraries
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
EA200900795A1 (ru) Вакцина
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
NZ741875A (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
EA201790680A1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) для популяции антигенов
MX2020005554A (es) Vacunas y composiciones inmunogenas para zika y metodos para usarlas.
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
WO2015112558A3 (en) Peptides, devices, and methods for the detection of anaplasma antibodies
WO2016210083A3 (en) Inactivated canine influenza vaccines and methods of making and uses thereof
WO2014128568A3 (en) Compositions and methods for treatment of hepatitis c
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
WO2014043220A3 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
EA201291437A1 (ru) Концентрация вакцинных антигенов без лиофилизации
AU2018388102A1 (en) Cross-immunizing antigen vaccine and method for preparation thereof
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
MX2016014868A (es) Metodos para secar por congelacion y rehidratar productos biologicos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: VARIATION BIOTECHNOLOGIES, INC. (CA)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: VARIATION BIOTECHNOLOGIES INC. (CA)